Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Colorectal cancer (CRC) is the third most common cancer worldwide. Surgical resection is one of the primary treatment options for CRC; however, postoperative recurrence remains a significant clinical challenge for both the medical community and patients. Postoperative chemotherapy, as an important adjuvant therapy, is widely used in CRC patients aiming to reduce the risk of recurrence. Despite extensive research on the efficacy of postoperative chemotherapy in CRC, the mechanisms of postoperative recurrence, predictive factors, and strategies to enhance chemotherapy effectiveness remain unclear. For colorectal cancer patients who have achieved NED (No Evidence of Disease), the decision to either reinitiate or change the systemic chemotherapy regimen for newly developed pulmonary oligometastases remains controversial. Local treatment options for diagnosing oligometastases include surgery, radiotherapy, and radiofrequency ablation. However, whether systemic treatment should be added after local treatment in patients who have achieved NED remains uncertain , and this issue requires urgent resolution.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rak jelita grubego, u którego nowotwór całkowicie ustąpił po leczeniu
- •Stan bez choroby utrzymywany przez co najmniej 6 miesięcy
- •Od pojawienia się przerzutów w płucach upłynęło co najmniej 6 miesięcy od osiągnięcia remisji
- •5 lub mniej ognisk przerzutów w płucach, które można poddać leczeniu niszczącemu
- •Ogólny stan zdrowia pozwalający na leczenie (wynik 0-2 w skali ECOG)
- •Oczekiwana długość życia co najmniej 3 miesiące
- •Prawidłowe funkcjonowanie wątroby, nerek, płuc i serca
- •Dobrowolna zgoda na udział w badaniu
✗ Disqualifies
- •Zaawansowany rak jelita grubego z przerzutami w momencie pierwszego rozpoznania
- •Więcej niż 5 przerzutów w płucach lub przerzuty w wątrobie, kościach lub węzłach chłonnych
- •Przerzuty w płucach, które nie można poddać radioterapii
- •Ciąża lub brak możliwości stosowania antykoncepcji przez rok od końca leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Department of Radiation Oncology, Shandong Cancer Hospital and Institute
Jinan, China
Trial contact
Jinbo Yue, Dorcter
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.